Overview

Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer

Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to look at how effective two drugs, nivolumab and ipilimumab, are for people with non-small lung cancer that has metastasized (has spread to other parts of the body) and to see what effects these drugs have on these tumors.
Phase:
Phase 2
Details
Lead Sponsor:
University Health Network, Toronto
Collaborator:
Bristol-Myers Squibb
Treatments:
Ipilimumab
Nivolumab